Roger L. Hawley

InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA.

AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA.

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.

Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA.

Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA.

Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA.

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.